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Background: Gene expression profiling is being widely applied in cancer research to identify biomarkers for clinical
endpoint prediction. Since RNA-seq provides a powerful tool for transcriptome-based applications beyond the
limitations of microarrays, we sought to systematically evaluate the performance of RNA-seq-based and microarray-
based classifiers in this MAQC-III/SEQC study for clinical endpoint prediction using neuroblastoma as a model.
Results: We generate gene expression profiles from 498 primary neuroblastomas using both RNA-seq and 44 k
microarrays. Characterization of the neuroblastoma transcriptome by RNA-seq reveals that more than 48,000 genes
and 200,000 transcripts are being expressed in this malignancy. We also find that RNA-seq provides much more
detailed information on specific transcript expression patterns in clinico-genetic neuroblastoma subgroups than
microarrays. To systematically compare the power of RNA-seq and microarray-based models in predicting clinical
endpoints, we divide the cohort randomly into training and validation sets and develop 360 predictive models on
six clinical endpoints of varying predictability. Evaluation of factors potentially affecting model performances reveals
that prediction accuracies are most strongly influenced by the nature of the clinical endpoint, whereas technological
platforms (RNA-seq vs. microarrays), RNA-seq data analysis pipelines, and feature levels (gene vs. transcript vs.
exon-junction level) do not significantly affect performances of the models.
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Conclusions: We demonstrate that RNA-seq outperforms microarrays in determining the transcriptomic characteristics
of cancer, while RNA-seq and microarray-based models perform similarly in clinical endpoint prediction. Our findings
may be valuable to guide future studies on the development of gene expression-based predictive models and their
implementation in clinical practice.Background
Microarray-based gene expression profiling is being widely
applied in cancer research to identify biomarkers for clin-
ical endpoint prediction, such as diagnosis, prognosis, or
prediction of treatment response [1–5]. The clinical value
of some of these classifiers is currently being examined in
prospective trials [6]. Within the MicroArray Quality
Control (MAQC)-II study [7], we observed, however, that
the performance of gene expression models in predicting
clinical outcome was limited and largely dependent on the
respective clinical endpoint.
The advent of next-generation sequencing technolo-
gies has revolutionized eukaryotic transcriptome analysis.
RNA deep-sequencing (RNA-seq) provides a powerful
tool to decipher global gene expression patterns far be-
yond the limitations of microarrays, including an unprece-
dented capability to discover novel genes, alternative
transcript variants, chimeric transcripts, and expressed
sequence variants as well as allele-specific expression
[8–12]. RNA-seq data have also been used to develop
gene expression-based predictive models in cancer re-
search [13, 14]. Considering the vast amount of add-
itional information provided by RNA-seq in comparison
to microarrays, it is tempting to speculate that RNA-
seq-based models may outperform microarray-based
models for clinical endpoint prediction. A comprehen-
sive comparison of RNA-seq and microarray-based pre-
dictive models, however, is lacking to date.
In this study of the Sequencing Quality Control (SEQC)
consortium, we therefore aimed to systematically investi-
gate the potential of RNA-seq-based classifiers in predict-
ing clinical endpoints in comparison to microarrays.
To this end, we selected neuroblastoma as a model, a
pediatric malignancy arising from the developing sympa-
thetic nervous system [15]. The clinical courses of neuro-
blastoma are remarkably heterogeneous ranging from
spontaneous regression to relentless progression. Accord-
ing to its diverse clinical presentations, patients are strati-
fied into different prognostic subgroups, with therapeutic
strategies ranging from ‘wait-and-see’ approaches to inten-
sive multimodal treatments. Thus, accurate prediction of
the natural course of the disease is an essential prerequis-
ite for risk estimation and tailoring therapy intensities in
individual patients. Treatment stratification in neuroblast-
oma is currently based on a combination of clinical and
molecular parameters, including tumor stage, patient ageat diagnosis, and the genomic amplification status of
the MYCN proto-oncogene. In addition, a number of
microarray-based gene expression models have been
proposed to predict neuroblastoma patient outcome
[16, 17]. However, while predictive models were highly
accurate in risk assessment of current low- and
intermediate-risk patients [18], the prediction of high-risk
patient outcome has remained challenging [18–20].
Here, we determined global gene expression profiles
from 498 primary neuroblastoma samples using both
RNA-seq and Agilent’s 44 k oligonucleotide-microarrays
to compare the performance of RNA-seq and microarray-
based models in predicting clinical endpoints. We gener-
ated 360 gene expression-based models using a broad
range of algorithms to predict six different endpoints with
a varying degree of predictability, and analyzed the effects
of a range of variables on the prediction performances.
We found that prediction accuracies were most strongly
influenced by the nature of the clinical endpoint, whereas
neither the expression profiling technology nor the RNA-
seq data analysis pipeline affected prediction accuracy sys-
tematically. To our knowledge, we present the first study
on the evaluation of predictive models using RNA-seq
in comparison to microarrays, which may provide valu-
able information for designing future experiments on
gene expression-based classifiers using high-throughput
technologies.
Results
Characterization of the neuroblastoma transcriptome
using RNA-seq
To comprehensively characterize the neuroblastoma
transcriptome, we sequenced 30,753,066,000 reads from
498 primary neuroblastoma samples covering the entire
spectrum of the disease (Table 1). Discontinuous align-
ment of sequence reads to the genome revealed that 98.86
% of the reads mapped to the reference (Additional file 1:
Figure S1; Additional file 2). We found that 348.5 Mbp
(11.26 %) of the genome were expressed in neuroblastoma
at a coverage threshold of 200, 197.7 Mbp (6.39 %) of
which represented exonic regions (Additional file 1:
FigureS2a). Within the expressed exome, 130.9 Mbp
covered annotated genes (coding, 40.5 Mbp; non-coding,
90.3 Mbp), while 66.8 Mbp of the genome represented
exonic regions not annotated in any of the databases
RefSeq/EntrezGene [21], AceView [22], or Gencode [23]
Table 1 Clinical characteristics of neuroblastoma patients
Number Percent of total
MYCN status
Normal 401 80.5 %
Amplified 92 18.5 %
N.A. 5 1.0 %
INSS stage
1 121 24.3 %
2 78 15.7 %
3 63 12.7 %
4 183 36.7 %
4S 53 10.6 %
Age at diagnosis
<18 months 300 60.2 %
>18 months 198 39.8 %
Sex
Male 278 55.8 %
Female 205 41.2 %
N.A. 15 3.0 %
High-risk patients 176 35.3 %
NA, not available
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Additional file 1: Figure S2b), corresponding to 39,052
novel exons supported by 118.4 Gbp (4.42 %) of the entire
sequence information of our study (Additional file 1:
Figure S2c).Fig. 1 Characteristics of the neuroblastoma transcriptome according to RN
mapped to distinct targets. b Number of genes, transcripts, and exon-junct
annotation by AceView. c Absolute numbers and overlap of differentially e
(blue) in four disease subgroups (see main text)In total, 88.75 % of the aligned reads mapped to genes
annotated in either of the reference databases RefSeq
(total number of genes annotated in the database, n =
24,536), AceView (n = 55,836), or Gencode (n = 56,071),
while 4.52 % of the reads mapped to newly discovered
exons or exon-junctions, 5.91 % to intronic and 0.65 %
to intergenic sequences (Fig. 1a). In the entire neuro-
blastoma cohort, we identified 48,415 genes expressed
above the background threshold when using AceView as
a reference database (Fig. 1b), corresponding to an aver-
age of 28,490 (±1,399) expressed genes per sample (Add-
itional file 1: Figure S3). By contrast, a total of 21,101
AceView genes were represented by the 44 k microarray
used in this study. Among all genes detected in neuro-
blastoma, 21,933 represented genes encoding conserved
proteins, 10,815 represented genes encoding mammalian-
specific proteins, 1,427 genes were classified as marginally
coding (that is, spliced genes with multiple alternative var-
iants, of which only a minority appear to be protein-
coding), and 14,240 represented non-coding genes. Fur-
thermore, the mapped reads supported a total of 204,352
transcripts annotated in AceView, comprising 319,231 an-
notated exon-junctions (Fig. 1b; mapping results using the
RefSeq and Gencode databases as references are given in
Additional file 1: Figure S4).
Analysis of differentially expressed genes (DEGs) in four
neuroblastoma subgroups
Since gene expression-based prediction of clinical end-
points depends on differing mRNA levels in clinically
relevant disease subgroups, we evaluated how analysis ofA-seq data using the Magic-AceView pipeline. a Percentage of reads
ions expressed in the entire neuroblastoma cohort according to their
xpressed genes (DEGs) identified by RNA-seq (red) and microarrays
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differential gene expression in four major clinico-genetic
subtypes of neuroblastoma (Additional file 1: Table S1).
We first restricted our analysis to the gene level consid-
ering only genes that were common to both platforms.
DEGs were identified from both platforms using two dif-
ferent analytical methods: (1) a method based on the
recommendations of the MAQC-I project utilizing a
fold-change ranking and a non-stringent P value cutoff
(MAQC-I) [7, 24, 25]; and (2) a novel method developed
within the MAQC-III project utilizing the expression
distributions, corrected for noise and batch effects, and
assisted by random resampling, to compute DEG scores
related to the Wilcoxon U test (Magic, see Additional
file 1: Supplementary Note 2). On the platform level, we
found that RNA-seq detected 5,488 (69.2 %) and 7,827
(67.0 %) of the DEGs identified by microarrays using the
MAQC-I and Magic methods, respectively (Additional
file 1: Figure S5). On the analytical method level, Magic
detected 7,423 (93.5 %) and 6,728 (80.4 %) of the DEGs
identified by the MAQC-I method using microarray and
RNA-seq data, respectively (Additional file 1: Figure S5).
Together, these results demonstrate that both the differ-
ent platforms and the different analytical methods pro-
vide largely comparable results, indicating the validity of
the methods used in our study.
To appreciate the comprehensive information provided
by RNA-seq for differential gene expression analysis, we
performed a second approach in which we applied the
Magic pipeline on the full AceView-annotated transcript
information in the four neuroblastoma subgroups. In total,
we detected 54,164 differentially expressed transcripts
corresponding to 21,315 DEGs using RNA-seq (RefSeq,
n = 14,251; AceView only, n = 7,064; Additional file 3).
By contrast, the 16,245 microarray probes found to be
differentially represented in the four subgroups corres-
pond to 11,688 DEGs (RefSeq, n = 10,308; AceView
only, n = 1,380). Notably, RNA-seq analysis identified
80.1 % of the DEGs detected by microarrays (Fig. 1c),
but in addition many more genes (annotated both in the
RefSeq database and in the AceView database only) than
microarrays (Additional file 1: Figure S6a). Furthermore,
the power of RNA-seq in discovering tumor subtype-
specific expression patterns became evident by detect-
ing genes with discordant expression patterns, that is,
genes with multiple transcript variants, of which at least
one variant was differentially expressed while at least
one other was not. We noted that 65.9 % of the 21,315
DEGs identified by RNA-seq showed such discordant
expression patterns. As an example, we detected differ-
entially expressed transcript variants of the cancer genes
NF1 and MDM4 (Additional file 1: Figure S7 and S8).
Both variants have been previously described to be of
functional relevance in other cancer entities [26, 27],and were identified by the transcript-based approach
only, while the gene-level analysis failed to report the
two genes as DEGs. As a particular subgroup of genes
with discordant expression patterns, we also determined
DEGs of which at least one transcript variant was upreg-
ulated while at least one other variant was downregu-
lated in the same subgroup. In this category, we
identified 1,073 DEGs by RNA-seq, as opposed to 129
DEGs by microarrays (Additional file 1: Figure S6b). Fo-
cusing on cancer census genes [28], we observed such
complex expression patterns for 26 of the current 513
cancer census genes (Additional file 1: Table S2). To-
gether, our findings substantiate that RNA-seq is a
powerful tool to determine the complex transcriptomic
characteristics of cancer.
Generation of predictive models from RNA-seq and micro-
array expression data
Given the comprehensive transcriptomic information
provided by RNA-seq and its power to identify DEGs,
we hypothesized that RNA-seq may improve gene
expression-based clinical endpoint prediction over mi-
croarrays. To evaluate this hypothesis, we utilized RNA-
seq and microarray-based expression data of all 498 pri-
mary neuroblastoma samples to predict six clinical end-
points: patients’ sex (SEX); the belonging to a patient
subgroup with extreme disease outcome (referred to as
CLASS LABEL, that is, event-free survivors without
chemotherapy for at least 1,000 days post diagnosis [fa-
vorable], or patients died from disease despite chemo-
therapy [unfavorable]); the occurrence of events, that is,
progression, relapse, or death (EFS ALL); the occurrence
of death from disease (OS ALL); and the occurrence of
events (EFS HR) and death from disease (OS HR) in the
subset of current high-risk patients (that is, patients with
stage 4 disease >18 months at diagnosis and patients of
any age and stage with MYCN-amplified tumors;
Table 2).
Analogous to the strategy used in the MAQC-II study
[7], the following best practice strategies were applied in
model development and validation to obtain reliable and
robust results: (1) Considering the fact that the nature of
the clinical endpoint strongly affects a classifier’s per-
formance [7, 18], we included endpoints that are known
to cover a broad range of predictive difficulties (low dif-
ficulty, SEX, and CLASS LABEL; intermediate difficulty,
EFS ALL, and OS ALL; high difficulty, EFS HR, and OS
HR). (2) We involved six data analysis teams and applied
various classification methods to take into account that
the proficiency of data analysis teams and the choice of
the classifier may impact the prediction results. (3) We
implemented a two-step modeling strategy to ensure an
unbiased validation: first, the models were developed
based on a training set and frozen; then, the validation
Table 2 Definition of clinical endpoints analyzed in this study
Cohort Endpoint (bin 1/0) Training set Validation set
# Samples 1 0 # Samples 1 0
All patients (498) SEX 249 103 146 249 108 141
(Female/Male)
EFS ALL 249 89 160 249 94 155
(Event yes/no)
OS ALL 249 51 198 249 54 195
(Death yes/no)
Class labeled patients (272) CLASS LABEL 136 45 91 136 46 90
(Unfavorable/Favorable)
High-risk patients (176) EFS HR 86 55 31 90 65 25
(Event yes/no)
OS HR 86 43 43 90 49 41
(Death yes/no)
EFS, event-free survival; HR, high risk; OS, overall survival
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We decided to focus not only on RefSeq-annotated genes
being the primary source of common microarrays designs,
but also to consider more comprehensive transcriptomic
information provided by the AceView database.
We extracted gene expression profiles from raw RNA-
seq data using three different processing pipelines for
mapping and quantifying sequence reads to also take the
potential influence of RNA-seq data processing on pre-
diction performances into account (Fig. 2a): (1) mapping
reads to the AceView reference using the Magic align-
ment tool (MAV); (2) mapping reads to AceView using
TopHat2 and Cufflinks (TAV); and (3) mapping reads to
the UCSC database together with RefSeq gene annota-
tions using TopHat2/Cufflinks (TUC). From the result-
ing data, we extracted gene expression profiles on three
different feature levels: (1) gene, (2) transcript, and (3)
exon-junction levels. Accordingly, each sample was asso-
ciated with 10 different expression profiles, including
one profile derived from microarray analyses (Fig. 2a).
Neuroblastoma samples were randomly divided into train-
ing and validation sets (Table 2). Data analysis teams gen-
erated predictive models using their methods of choice,
and submitted their best model for each of the six differ-
ent endpoints on every expression profile, resulting in a
total of 360 models. Afterwards, the models were used to
predict endpoints in the validation set, and the external
performance of each model was evaluated after unblinding
the clinical information using various performance met-
rics (Additional files 4 and 5).
Clinical endpoint prediction by RNA-seq- and
microarray-based models
We determined prediction performances of all models in
terms of MCC for each endpoint in the validation set,and compared performances of RNA-Seq and microarray-
based models. RNA-seq-based models performed signifi-
cantly better than microarray-based models in predicting
endpoint EFS ALL (P = 0.043), while models based on the
two platforms performed similarly well in predicting the
remaining five endpoints (Fig. 2b).
In line with our findings from the MAQC II study [7],
we noticed that prediction performances were strongly
influenced by the respective clinical endpoint. While pa-
tient’s SEX and CLASS LABEL were predicted accur-
ately, performances were substantially inferior for
predicting EFS and OS in the entire cohort, and even
worse in the high-risk subgroup by both RNA-seq and
microarray-based models (Fig. 2b). To assess the poten-
tial clinical value of gene expression-based outcome pre-
diction, we performed univariate Cox regression analysis
and Kaplan-Meier survival estimates for patients of the
validation set using the best performing RNA-seq and
microarray models. The models significantly discrimi-
nated patients with favorable and unfavorable outcome
in the entire cohort and in the class labeled cohort
(Additional file 1: Figure S9a-d, Table S3 and S4), which
is consistent with previous observations made by us and
others [16–18, 20]. In the high-risk cohort, the best per-
forming models were also able to predict patient outcome,
which was in contrast to the prognostic markers age, stage
and MYCN status (Additional file 1: Figure S9e and f, Fig.
S10, and Table S5). The potential relevance of gene
expression-based outcome prediction for neuroblastoma
patients was substantiated by multivariate Cox regression
analysis (Additional file 1: Table S6).
We also assessed whether performances observed in
the validation set could have been estimated from per-
formances determined in the internal cross-validation
processes (Fig. 2c and d). Strikingly, correlations of
Fig. 2 Performances of RNA-seq- and microarray-based models to predict clinical endpoints in the validation cohorts. a Schematic overview of
gene expression profiles generated by RNA-seq (n = 9 per sample) and microarray (n = 1 per sample). CL, Cufflinks; MAV, Magic-AceView; TAV,
TopHat-AceView; TUC, TopHat-UCSC. b Distribution of MCC values of all models for each endpoint according to the technical platform (MA,
microarray). Boxes indicate the 25 % and 75 % percentiles, and whiskers indicate the 5 % and 95 % percentiles; (*), P <0.05; two-sided T-test was
performed for statistical testing. c, d Model performance of internal validation compared with external validation based on (c) microarray and
(d) RNA-seq expression data in terms of MCC
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array- and RNA-seq-based models were almost identical
(r = 0.716 and r = 0.723, respectively), indicating that
the technical platform does not affect the reliability of
performance estimates obtained during model training.
It has to be noted, though, that performances of both
RNA-seq- and microarray-based models for endpoints
EFS HR and OS HR tended to be biased strongly to-
wards internal validation, which is indicative of model
overfitting on the training set. These results suggest that
the endpoint itself influences the reliability of perform-
ance estimates derived from training cohorts.Variables affecting prediction performances of
RNA-seq-based models
We next aimed to identify additional variables that may
affect prediction performances of RNA-seq-based models.
In general, models derived from distinct processing pipe-
lines and distinct feature levels did not differ significantly
in their prediction performances with few exceptions
(Fig. 3a and b). To investigate systematically which vari-
ables may affect model performances, we performed vari-
ance component analysis using Mixed Modeling [29]. We
found that 95 % of the variation across MCC values was
caused by effects of the endpoints, with lowest variances
Fig. 3 Analysis of factors potentially affecting prediction performances of RNA-seq-based models. a Distribution of MCC values of all models for
each endpoint according to RNA-seq data processing pipelines (MAV, Magic-AceView; TAV, TopHat-AceView; TUC, TopHat-UCSC). b Distribution of
MCC values of all models for each endpoint according to feature levels, that is, gene, transcript (TS), and exon-junction (Jct) levels
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Additional file 1: Table S7). Of the remaining 5 % of vari-
ability, 1.5 % was explained by four statistically significant
effects. The size of the model (that is, the number of fea-
tures included in the model) was the only factor that sig-
nificantly affected prediction performances independent
of the endpoint. On average, models comprising 100 to
1,000 features gave the best prediction results (Fig. 4b).
The model size effect, however, differed between the end-
points analyzed: For prediction of the two endpoints that
were easy to predict (SEX and CLASS LABEL), only one
to 10 features were required, while more complex models
improved prediction results for the remaining endpoints
(Additional file 1: Figure S11a). In addition, different
analysis teams and different modeling methods had
varying performances across the endpoints (Additional
file 1: Figure S11b and c). The remaining 3.5 % were re-
sidual variance not explained by any of the factors under
investigation (Fig. 4a). Taken together, our data demon-
strate that microarray and RNA-seq models perform
similar in clinical endpoint prediction, and that the
RNA-seq processing pipeline and the feature level do
not influence prediction performances systematically.
We finally aimed to evaluate how different parts of the
transcriptome contribute to the performance of predict-
ive models. For this purpose, we determined the fraction
of RefSeq-annotated features, protein coding features,
and spliced features in MAV and TAV models both on
the gene and transcript level. We found that the propor-
tion of coding and spliced features in the models largelyreflected the proportion of coding and spliced features
in the AceView database (Additional file 1: Figure S12
and Table S8). Similarly, the proportion of RefSeq-
annotated features in the models was in the range of
their proportion in the AceView database. Taking all
endpoints into account, however, we observed that pre-
diction accuracies were significantly correlated with the
fraction of RefSeq features, coding features, and spliced
features in the models both on the gene and the tran-
script level (Fig. 5, Additional file 1: Figure S13). These
data indicate that the composition of prediction models
depends on the predictability of the clinical endpoints in
general.
Discussion
Here, we evaluated the potential of RNA-seq to predict
clinical endpoints in comparison to microarrays. We
generated gene expression profiles from 498 primary
neuroblastoma samples using RNA-seq and microarrays,
which represents, to the best of our knowledge, the most
comprehensive description of a single cancer entity’s
transcriptome. We demonstrate that gene expression
profiles of neuroblastoma are tremendously complex,
corresponding to findings on the transcriptomic land-
scape of other human cells published recently [9, 12,
30]. In the entire neuroblastoma cohort, we found
48,415 genes and 204,352 transcripts to be expressed,
comprising 86.7 % and 77.3 % of all features annotated
in the AceView database, respectively. We also identified
>39,000 novel exons to be expressed in neuroblastoma,
Fig. 4 a Contribution of different factors to the variability of
prediction results as assessed by variance component analysis. (*),
P <0.05; (**), P <0.01. The factors platform, RNA-seq pipeline, feature
level, analysis team, classification method, and model size were
analyzed both independently of the endpoint (white box), and taking
a potential endpoint-dependence into account (gray box). b Best linear
unbiased predictor (BLUP) estimates for the log10(model size) as the
single factor contributing significantly to the prediction variability
independent of the endpoint. Note that BLUPs are centered around zero
and effectively average over all other effects. BLUPs for Log10(Model
Size) indicate that models with 100 to 1,000 features perform better
than those with fewer or more features
Fig. 5 Correlation of prediction performances with the feature composition
plotted against the fraction of RefSeq-annotated genes (a), the fraction of p
genes or transcripts consisting of at least two exons; (c) in the model
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tome still exceeds the complexity reflected by current
reference databases such as RefSeq, Gencode, and Ace-
View. The comparison of gene expression profiles of
four major clinico-genetic subgroups revealed that RNA-
seq identified almost twice as many DEGs as microar-
rays. Of note, DEGs determined by RNA-seq comprised
80.1 % of the DEGs detected by microarrays, pointing
towards the reliability of identifying DEGs by either
method. One reason for the discrepant numbers re-
ceived by RNA-seq and microarrays derives from the
fact that 6,939 DEGs identified by RNA-seq were not
represented by a probe on the microarray. In addition,
4,776 DEGs were not detected by microarrays although
the genes were represented by a probe, which may be at
least partly attributed to our analytical approach which
was taking expression profiles at the transcript level into
account. Taken together, our study substantiates that
RNA-seq is capable of providing much more detailed in-
sights into the transcriptomic characteristics of neuro-
blastoma than microarrays.
To systematically compare the potential of RNA-seq-
and microarray-based models for clinical endpoint pre-
diction, we utilized various data annotation pipelines
and considered different feature levels to establish nine
expression profiles per sample derived from RNA-seq
data, complemented by one expression profile derived
from microarray analyses. We generated 360 predictive
models for six endpoints covering a broad range of pre-
diction difficulties. Evaluation of the prediction perfor-
mances in the validation set revealed that the endpoint
represents the most relevant factor affecting model per-
formances, which is well in line with the findings of the
MAQC-II study [7]. By contrast, neither the technical
platform (that is, RNA-seq vs. microarrays) nor the
RNA-seq data annotation pipeline significantly affected
the variability of prediction performances. Collectively,of prediction models. MCC values of MAV and TAV models were
rotein-coding genes (b), and the fraction of spliced genes (that is,
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based models perform similarly in clinical endpoint
prediction.
We also noticed that models based on different feature
levels predicted clinical endpoints with comparable ac-
curacies. In turn, this result implies that models based
on exon-junction levels perform equally well as models
based on gene levels. These findings may impact the
development of expression-based classifiers to be used
in clinical settings, which are frequently transferred
from high-throughput analyses to RT-qPCR-based as-
says [6, 20]: While assays based on gene expression
levels may lack specificity due to uncertainties on the
underlying relevant transcript variants, exon-junctions
identified by RNA-seq provide an unambiguous source
of expression information for developing specific diag-
nostic tests.
Our results do not support the hypothesis that the
more extensive transcriptomic information provided by
RNA-seq in comparison to microarrays may improve
gene expression-based prediction performances in gen-
eral. A possible explanation for this finding might be
that the inherent complexity of RNA-seq data may
promote over-fitting effects in the model development
process, leading to over-optimistic internal prediction
performances that cannot be reproduced in external
validation cohorts [31]. We noted, however, that the
correlation of internal and external validation perfor-
mances was almost identical for RNA-seq and microarray-
based models, indicating that over-fitting effects are inde-
pendent of the technological platform. An alternative
explanation for our results may be inferred from the obser-
vation that the proportion of RefSeq-annotated features in
the prediction models was in the range of, or even above
their proportion in the AceView database for most end-
points. This finding may suggest that the predictive infor-
mation of RefSeq-annotated genes represented by standard
microarrays is saturated, and that predictive information of
more complex transcriptomic data provided by RNA-seq
is largely redundant. It has to be noted, though, that
models for endpoints that were difficult to predict (that is,
EFS HR, OS HR) tended to disproportionately recruit fea-
tures that are not annotated in RefSeq, suggesting that
these features may considerably contribute to the predic-
tion accuracy in these endpoints.
Both gene expression-based models derived from
RNA-seq and microarray analyses were capable of pre-
dicting patient outcome in the entire neuroblastoma co-
hort accurately, thereby validating results from previous
studies and underscoring their potential clinical utility
for risk estimation in neuroblastoma [16–18, 20]. Not-
ably, we observed that models containing 100 to 1,000
features on average performed better than models con-
taining fewer features. This finding may argue againstambitious efforts to minimize feature numbers in predict-
ive models, as has been done in the past [20, 32]. In
addition, we found that the best performing models
were able to predict outcome of high-risk patients with
a similar precision as previously published multigene
signatures [18, 20, 33], and independently from current
prognostic markers. While the prognostic value of
such multigene signatures needs to be validated in in-
dependent high-risk neuroblastoma cohorts, these
findings may represent a starting point to establish
biomarker-based risk assessment in this challenging
patient subgroup.
Conclusions
Our study demonstrates that RNA-seq based models are
suitable for clinical endpoint prediction, and that pre-
diction performances are similar to those of microarray-
based models. Our findings may be used to guide the
design of future studies for developing gene expression-
based predictive models as well as their implementation
in clinical practice. The key advantage of RNA deep-
sequencing, however, resides in its ability to characterize
transcriptomes at an unprecedented level of detail, which
may lead to new insights into the molecular mechanisms
of disease, thereby providing starting points for the devel-
opment of rational targeted therapeutic strategies.
Methods
Patient samples
This project comprised tumor samples of 498 neuro-
blastoma patients from seven countries: Belgium (n = 1),
Germany (n = 420), Israel (n = 11), Italy (n = 5), Spain
(n = 14), United Kingdom (n = 5), and United States
(n = 42). All patients were registered in respective clinical
trials with informed consent. The patients’ age at diagnosis
varied from 0 to 295.5 months (median age, 14.6 months).
Tumor stage was classified according to the International
Neuroblastoma Staging System (INSS): stage 1 (n = 121;
MYCN-amplified (MNA), n = 3), stage 2 (n = 78; MNA,
n = 5), stage 3 (n = 63; MNA, n = 15), stage 4 (n = 183;
MNA, n = 65), stage 4S (n = 53; MNA, n = 4). Events
were defined according to a revised version of the Inter-
national Neuroblastoma Response Criteria [34].
Gene expression analysis using oligonucleotide
microarrays and RNA-sequencing
Tumor material preparation was performed as described
previously [16]. For microarray analysis, gene expression
profiles were generated using customized 4x44k oligo-
nucleotide microarrays (Agilent Technologies). Sample
preparation, labeling, and hybridization were performed
according to the manufacturer’s protocol. Microarray
expression profiles were generated using Agilent’s Fea-
ture Extraction software (Version 9.5.1) [35]. For RNA
Zhang et al. Genome Biology  (2015) 16:133 Page 10 of 12sequencing, Dynabeads® mRNA Purification Kit (Invitro-
gen) was used to purify mRNA from total RNA, and
ERCC RNA spike-in was added according to the user
guide. Library construction was performed according to
the non-stranded TruSeqs™ protocol. Clusters were gen-
erated according to the TruSeq PE cluster Kit v3 reagent
preparation guide (for cBot-HiSeq/HiScanSQ). High-
throughput shotgun sequencing was performed on the
Illumina HiSeq 2000 platform. Paired-end reads with
lengths of 90 and 100 nucleotides were generated for 12
samples and 486 samples, respectively.
Raw data preprocessing, read mapping, and gene
expression quantification
In addition to the microarray expression profiles, three
different RNA-seq processing pipelines were applied to
generate expression profiles from the sequencing raw
data.
(1). The Magic-AceView pipeline (MAV) is based on
the Magic analysis tool [22] (ftp://ftp.ncbi.nlm.nih.
gov/repository/acedb/Software/Magic). Magic
includes quality control, alignment, annotation,
quantification, and normalization of RNA-seq data.
Magic maps the read pairs in parallel on all
targets, including the genome (NCBI 37), the
RefSeq 37.104, the Gencode v15, and the
AceView 2011 gene models. Gene expression is
measured in sFPKM, adding to the standard
FPKM (fragments per kilobase of transcript per
million mapped reads) a gene-specific and
experiment-specific threshold of significance
(sFPKM) for low counts, together with a
number of batch effect corrections. The
Magic-AceView pipeline is described in detail as
a Supplementary Note 1 (Additional file 1).
(2). For the TopHat-AceView (TAV) pipeline, raw reads
of RNA-seq were filtered using an in-house pipeline
(BGI, Shenzhen, PR China). Clean RNA reads were
aligned to the human genome (hg19) using TopHat
[36]. Cufflinks was used to quantify the gene as
well as transcript expression [37]. FPKM values for
each annotated gene in the AceView database were
calculated.
(3). For the TopHat-UCSC pipeline (TUC), RNA-seq
reads were mapped by TopHat [36] to a
reference sequence consisting of the UCSC hg19
human genome and the RefSeq annotated genes.
The mapped reads were processed by Cufflinks
1.3.0 with default parameters to assemble
transcripts relying on RefSeq annotation [37].
Gene- and transcript-level expression values
were computed by Cufflinks in terms of FPKM
and transformed as log2(1 + FPKM) fordownstream processing. Reads that align to
known junctions were quantified by the Open
Source software bam2ssj [38].Construction of classification models
Six data analysis teams received 10 expression profiles
(nine profiles based on RNA-seq data and one profile
based on microarray data) to predict six different end-
points as extensively described in the Results. Data ana-
lysts were asked to include a five-fold cross validation
for 10 iterations to assess model performances in the
training datasets, but were otherwise free in their choice
of modeling algorithms and statistical tests to generate
and select suitable prediction models. Models with highest
average performance metrics were selected and submitted
for testing on adequate blinded validation sets for each
endpoint. More details and an overview of the applied
classification algorithms are given in Additional file 1
(Supplementary Note 3 and Table S9).Prediction performance evaluation and statistical analyses
Matthew’s correlation coefficient (MCC) was used to evalu-
ate the prediction performance of classification models as
described [7]. Differences in model performances were sub-
jected to variance component analysis using Mixed Model-
ing [29]. All the six major effects were assigned to random
effects for partitioning their corresponding variances from
total variance. Statistical F- and T- tests were applied for
evaluating the significance of corresponding variance com-
ponents and comparisons among the levels within each
variance component, respectively. For statistical analysis of
clinical data, IBM SPSS package release 20.0.0 and version
2.15.0 of the survival package in R was applied [39]. Overall
survival (OS) was calculated as the time from diagnosis to
death from disease or the last follow-up if the patient sur-
vived. Event-free survival (EFS) was calculated from diag-
nosis to the time of tumor progression, relapse, or death
from disease or to the last follow-up if no event occurred.
Survival curves were computed according to Kaplan-Meier
estimates and compared with the log-rank test. Univariate
Cox proportional hazards or logistic regression was applied
with respect to EFS and OS to analyze the separate prog-
nostic value of gene expression-based classification models
or clinical markers, considering P <0.05 as significant. All
analyses are regarded as explorative.Data availability
Microarray and RNA-seq data can be accessed from the
GEO database (www.ncbi.nlm.nih.gov/geo/) with ac-
cession numbers GSE49710 and GSE49711, respect-
ively, which are included in SEQC Project SuperSeries
GSE47792.
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Additional file 1: This file contains Supplementary Figures S1–S13,
Supplementary Tables S1–S9, and Supplementary Notes 1–3 on the
Magic-AceView pipeline, differential gene expression methods, and
methodology on the generation of prediction models.
Additional file 2: This file contains Supplementary Data: RNA-seq
information of 498 neuroblastoma samples: Read fate and mapping
targets.
Additional file 3: This file contains Supplementary Data: Genes and
transcript differentially expressed between four clinico-genetic
neuroblastoma subgroups.
Additional file 4: This file contains Supplementary Data: Internal
cross-validation performance and external validation performance
of 360 submitted prediction models.
Additional file 5: This file contains Supplementary Data: Clinical
characteristics and sample statistics for 498 neuroblastoma
patients.
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